ACG Wealth’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $1.21M | Buy |
27,727
+843
| +3% | +$41K | 0.28% | 92 |
|
|
2022
Q2 | $1.41M | Sell |
26,884
-12
| -0% | -$612 | 0.29% | 87 |
|
|
2022
Q1 | $1.39M | Sell |
26,896
-2,064
| -7% | -$107K | 0.26% | 101 |
|
|
2021
Q4 | $1.71M | Sell |
28,960
-3,774
| -12% | -$187K | 0.24% | 97 |
|
|
2021
Q3 | $1.41M | Buy |
32,734
+1,996
| +6% | +$88.4K | 0.19% | 110 |
|
|
2021
Q2 | $1.2M | Buy |
30,738
+2,709
| +10% | +$105K | 0.15% | 126 |
|
|
2021
Q1 | $1.01M | Sell |
28,029
-3,076
| -10% | -$109K | 0.13% | 128 |
|
|
2020
Q4 | $1.15M | Sell |
31,105
-3,873
| -11% | -$142K | 0.16% | 118 |
|
|
2020
Q3 | $1.22M | Buy |
34,978
+3,901
| +13% | +$137K | 0.18% | 104 |
|
|
2020
Q2 | $964K | Sell |
31,077
-691
| -2% | -$23.5K | 0.16% | 122 |
|
|
2020
Q1 | $984K | Sell |
31,768
-278
| -0.9% | -$9.47K | 0.18% | 110 |
|
|
2019
Q4 | $1.19M | Sell |
32,046
-519
| -2% | -$18.5K | 0.18% | 117 |
|
|
2019
Q3 | $1.11M | Buy |
32,565
+2,757
| +9% | +$100K | 0.16% | 133 |
|
|
2019
Q2 | $1.23M | Sell |
29,808
-589
| -2% | -$23.4K | 0.16% | 131 |
|
|
2019
Q1 | $1.23M | Sell |
30,397
-4,909
| -14% | -$197K | 0.16% | 126 |
|
|
2018
Q4 | $1.46M | Buy |
35,306
+1,762
| +5% | +$73.1K | 0.22% | 93 |
|
|
2018
Q3 | $1.4M | Buy |
33,544
+531
| +2% | +$20.4K | 0.19% | 110 |
|
|
2018
Q2 | $1.14M | Buy |
33,013
+2,755
| +9% | +$94.1K | 0.17% | 115 |
|
|
2018
Q1 | $1.02M | Buy |
30,258
+3,694
| +14% | +$127K | 0.15% | 126 |
|
|
2017
Q4 | $913K | Buy |
26,564
+1,530
| +6% | +$52.2K | 0.14% | 142 |
|
|
2017
Q3 | $848K | Sell |
25,034
-12,927
| -34% | -$415K | 0.15% | 128 |
|
|
2017
Q2 | $1.21M | Buy |
37,961
+9,150
| +32% | +$289K | 0.2% | 121 |
|
|
2017
Q1 | $935K | Buy |
28,811
+5,696
| +25% | +$180K | 0.17% | 123 |
|
|
2016
Q4 | $712K | Sell |
23,115
-2,145
| -8% | -$65.5K | 0.15% | 118 |
|
|
2016
Q3 | $812K | Buy |
25,260
+4,298
| +21% | +$144K | 0.17% | 114 |
|
|
2016
Q2 | $700K | Buy |
20,962
+730
| +4% | +$23.3K | 0.16% | 118 |
|
|
2016
Q1 | $569K | Sell |
20,232
-61,228
| -75% | -$1.75M | 0.13% | 126 |
|
|
2015
Q4 | $2.5M | Sell |
81,460
-861
| -1% | -$27.1K | 0.56% | 53 |
|
|
2015
Q3 | $2.45M | Buy |
82,321
+7,671
| +10% | +$246K | 0.66% | 45 |
|
|
2015
Q2 | $2.38M | Sell |
74,650
-5,123
| -6% | -$167K | 0.59% | 51 |
|
|
2015
Q1 | $2.63M | Sell |
79,773
-13,873
| -15% | -$441K | 0.7% | 44 |
|
|
2014
Q4 | $2.77M | Sell |
93,646
-2,154
| -2% | -$61.8K | 0.75% | 36 |
|
|
2014
Q3 | $2.69M | Sell |
95,800
-68,381
| -42% | -$1.92M | 0.76% | 34 |
|
|
2014
Q2 | $4.62M | Buy |
164,181
+69,811
| +74% | +$1.99M | 0.87% | 39 |
|
|
2014
Q1 | $2.88M | Sell |
94,370
-26,859
| -22% | -$801K | 0.85% | 25 |
|
|
2013
Q4 | $3.52M | Buy |
121,229
+49,810
| +70% | +$1.45M | 0.9% | 26 |
|
|
2013
Q3 | $1.95M | Sell |
71,419
-31,349
| -31% | -$853K | 0.8% | 46 |
|
|
2013
Q2 | $2.73M | Buy |
+102,768
| New | +$2.84M | 1.07% | 24 |
|
Other funds holding PFE
ACG Wealth's PFE Position: Q3 2022 in Review
ACG Wealth increased its Pfizer (PFE) stake by 3.1% in Q3 2022, buying an estimated $41K and bringing the position to 27,727 shares worth $1.21M. The position accounts for 0.28% of the portfolio, ranked #92.
ACG Wealth first reported a position in PFE in Q2 2013 and has held it in 38 quarters since. The position peaked at $4.62M in Q2 2014. 3,085 funds tracked by Wall St. Rank hold PFE as of Q3 2022.
- ACG Wealth held 27,727 shares of Pfizer worth $1.21M as of Q3 2022.
- ACG Wealth bought 843 Pfizer shares in Q3 2022, an estimated $41K.
- Pfizer made up 0.28% of ACG Wealth's portfolio in Q3 2022, its #92 holding.
- ACG Wealth first reported a position in Pfizer in Q2 2013 and has held it in 38 quarters since.
- ACG Wealth's Pfizer position peaked at $4.62M in Q2 2014.
- 3,085 funds tracked by Wall St. Rank held Pfizer as of Q3 2022.
Based on ACG Wealth's 13F filing for Q3 2022, filed 3 Nov 2022.